Dose-Response Relationships of RU 486

References

• Philibert D, Deraedt R, Teutsch G. RU 38486: a potent antiglucocorticoid, in vivo. Eighth International Congress of Pharmacology, Tokyo, July, 19-241981, Abstract No. 1463
   Google Scholar
• Philibert D, Deraedt R, Teutsch G, Tournemine C, Sakiz E. RU 486: a new lead for steroidal anti-hormones. Sixty-fourth Annual Meeting of the Endocrine Society, San Francisco, June, 16-181982, Abstract No. 688
   Google Scholar
• Heikinheimo O, Lähteenmäki P, Kolvunen E, et al. Metabolism and serum binding of RU 486 in women after various single doses. Hum Reprod 1987; 2: 379–85
   PubMed Web of Science ®Google Scholar
• Heikinheimo O. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. J Steroid Biochem 1989; 32: 21–5
   PubMedGoogle Scholar
• Deraedt R, Bonnat C, Busigny M, . Pharmacokinetics of RU 486. The antiprogestin steroid RU 486 and human fertility control., E E. Baulieu, S Segal, et al. Plenum Press, New York 1985; 103–22
   Google Scholar
• Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukainen T, Lähteenmäki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem 1987; 26: 279–84
   PubMedGoogle Scholar
• Moguilewsky M, Philibert D. Biochemical profile of RU 486. The antiprogestin steroid RU 486 and human fertility control., E E. Baulieu, S Segal. Plenum Press, New York 1985; 87–97
   Google Scholar
• Birgerson L. Termination of early human pregnancy with anti-progestational agents. Thesis, Uppsala University, Sweden 1990
   Google Scholar
• Paxton J. Alpha 1-acid glycoprotein and binding of basic drugs. Methods Find Exp Clin Pharmacol 1983; 5: 635–48
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Koyama J, Yamashina I. Isolation and characterization of a1-acid glycoprotein from rat serum. J Biochem 1966; 60: 554–60
   Web of Science ®Google Scholar
• Wolf J, Danforth D, Ulmann A, Baulieu E E., Hodgen G. Contraceptive potential of RU 486 by ovulation inhibition. II. Suppression of pituitary gonadotropin secretion in vitro. Contraception 1989; 40: 185–98
   PubMed Web of Science ®Google Scholar
• Lamberts S, Bons E, Ultterlinden P. Studies on the glucocorticoid-receptor blocking action of RU 38486 in cultured ACTH-secreting human pituitary tumor cells and normal rat pituitary cells. Acta Endocrinol 1985; 109: 64–9
   PubMedGoogle Scholar
• Pesonen U, Koulu M, Heikinheimo O, Huupponen R. The glucocorticoid antagonist mifepristone reveals abnormal regulation of the adrenocorticol system in obese Zucker rats. J Endocrinol 1992; 132: 425–31
   PubMed Web of Science ®Google Scholar
• Bertagna X, Bertagna C, Luton J P., Husson J M., Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 1984; 59: 25–8
   PubMed Web of Science ®Google Scholar
• Gaillard R, Riondel A, Müller A, Herrmann W, Baulieu E E. RU 486: a steroid with antiglucocorticosteroid activity that disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci USA 1984; 81: 3879–82
   PubMed Web of Science ®Google Scholar
• Kettel M, Liu J, Murphy A, Ulmann A, Mortola J, Yen S. Endocrine responses to long-term administration of the antiprogesterone RU 486 in patients with pelvic endometriosis. Fertil Steril 1991; 56: 402–7
   PubMed Web of Science ®Google Scholar
• Laue L, Chrousos G, Lorlaux D, et al. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man. J Clin Endocrinol Metab 1988; 66: 290–3
   PubMed Web of Science ®Google Scholar
• Liu J, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen S. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU 486. J Clin Endocrinol Metab 1987; 65: 1135–40
   PubMed Web of Science ®Google Scholar
• Shoupe D, Van den Page M, Madkour H, Spitz I, Lobo R. Effects of the antiprogesterone RU 486 in normal women, II administration in the late follicular phase. Am J Obstet Gynecol 1987; 157: 1421–6
   PubMed Web of Science ®Google Scholar
• Permezel M, Lenton E, Roberts I, Cooke I. Acute effects of progesterone and the antiprogestin RU 486 on gonadotropin secretion in the follicular phase of the menstrual cycle. J Clin Endocrinol Metab 1989; 68: 960–5
   PubMed Web of Science ®Google Scholar
• Batista M, Cartledge T, Zellmer A, Nieman L, Merrlam G, Loriaux L. Evidence for critical role of progesterone in the regulation of the midcycle gonadotrophln surge and ovulation. J Clin Endocrinol Metab 1992; 74: 565–70
   PubMed Web of Science ®Google Scholar
• DiMattlna M, Albertson B, Tyuson V, Loriaux L, Falk R. Effect of the antiprogestin RU 486 on human ovarian steroidogenesis. Fertil Steril 1987; 48: 229–33
   PubMed Web of Science ®Google Scholar
• Parlnaud J, Perret B, Ribbes H, Vieitez G, Bauiieu E E. Effects of RU 486 on progesterone secretion by human preovulatory granulosa cells in culture. J Clin Endocrinol Metab 1990; 70: 1534–7
   PubMed Web of Science ®Google Scholar
• Kekkonen R, Alfthan H, Haukkamaa M, Heikinheimo O, Luukkalnen T, Lähteenmäkl P. Interference with ovulation by sequential treatment with the antiprogesterone RU 486 and synthetic progestin. Fertil Steril 1990; 53: 747–50
   PubMed Web of Science ®Google Scholar
• Luukkalnen T, Heikinheimo O, Haukkamaa M, Lähteenmäkl P. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. Fertil Steril 1988; 49: 961–3
   PubMed Web of Science ®Google Scholar
• Ulmann A. RU 486: the French Experience. Terra Symposia III. Progesterone antagonists. New developments in reproductive biology and oncology, Lake Paltz, May, 25-291992, Abstract No: 52
   Google Scholar
• Couzinet B, Van den Strat N, Ulmann A, Baulieu E E., Schaison G. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). N Engl J Med 1986; 315: 1565–9
   PubMed Web of Science ®Google Scholar
• Mlshell D, Jr, Shoupe D, Brenner P, et al. Termination of early gestation with the anti-progestin steroid RU 486: medium versus low dose. Contraception 1987; 35: 307–21
   PubMed Web of Science ®Google Scholar
• Birgerson L, Odlind V. The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. Contraception 1988; 38: 391–400
   PubMed Web of Science ®Google Scholar
• Rodger M, Balrd D. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet 1987; ii: 1415–18
   Google Scholar
• Rodger M, Baird D. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analogue (gemeprost). Contraception 1989; 40: 439–48
   PubMed Web of Science ®Google Scholar
• WHO. Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertil Steril 1991; 56: 32–40
   PubMed Web of Science ®Google Scholar
• Grimes D, Bernstein L, Lacarra M, Shoupe D, Mlshell D, Jr. Predictors of failed attempted abortion with the antiprogestin mifepristone (RU 486). Am J Obstet Gynecol 1990; 162: 910–17
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Yllkorkala O, Turpeinen U, Lähteenmäkl P. Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486. Acta Endocrinol 1990; 123: 298–304
   PubMedGoogle Scholar
• Gupta J, Johnson N. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix. Lancet 1990; 335: 1238–40
   PubMed Web of Science ®Google Scholar
• Lefebvre Y, Proulx L, Elie R, Poulin O, Lanza E. The effects of RU 486 on cervical ripening. Am J Obstet Gynecol 1990; 162: 61–5
   PubMed Web of Science ®Google Scholar
• Cheang A, Ho K, Sen D, Ratman S. A placebo-controlled, dose finding study of the antiprogestin RU 486 for preoperative cervical dilatation. First International Conference on Reproductive Endocrinology, Beijing, November, 2-61988, Abstract No. 34
   Google Scholar
• Heikinheimo O, Tevelin M, Shoupe D, Croxatto H, Lähteenmäkl P. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. Contraception 1986; 34: 613–24
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Haukkamaa M, Lähteenmäkl P. Distribution of RU 486 and its demethylated metabolites in human. J Clin Endocrinol Metab 1989; 68: 270–5
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Pesonen U, Huupponen R, Koulu M, Lähteenmäkl P. First-pass metabolism and distribution of RU 486 and its metabolites in rats. Terra Symposia III. Progesterone, antagonists. New developments in reproductive biology and oncology, Lake Paltz, NY, May, 25-291992, (in press)
   Google Scholar